Efficacy and Safety of Infliximab Biosimilar (REMSIMA) in Patients with Ankylosing Spondylitis after switching from Infliximab Reference Product: 12 Months Comparative Open Label Study

Published: 17 December 2021| Version 1 | DOI: 10.17632/wj88v4zwwm.1
Abdulsatar Mathkhor


Infliximab biosimilar (REMSIMA) has the same of efficacy and safety profile in the treatment of patients with Ankylosing Spondylitis (AS) previously was on infliximab reference product (RP). Because of the shortage and the expense of biological drugs in our country, so; there is an urgent need for switching from the originator to its biosimilar; therefore, we conducted this study to investigate the efficacy and safety of switching to CT-P13 (Remsima) in AS patients previously treated with infliximab RP (Remicade).



Biologicals in Rheumatology